Biolegend, 372706, APC anti-human TIGIT (VSTM3) Antibody, 100tests

T cell immunoreceptor with Ig and ITIM domains (TIGIT), also known as VSTM3 or WUCAM, is a 26 kD, type I transmembrane protein and is a member of the PVR (poliovirus receptor) family of immunoglobulin-like domain containing proteins. TIGIT is expressed on activated T cells, follicular T helper, memory, and regulatory T cells as well as on NK cells. TIGIT is a negative regulator of NK and T cell activation. Expression of TIGIT is associated with decreased functionality of CD8 T cells in chronic viral infection and tumors. TIGIT also promotes the differentiation of tolerogenic phenotype in dendritic cells with an increased secretion of IL-10 and a diminished production of IL-12.
100tests
Verified Reactivity: Human
Antibody Type: Monoclonal
Host Species: Mouse
Immunogen: Recombinant Human TIGIT.
Formulation: Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA)
Preparation: The antibody was purified by affinity chromatography and conjugated with APC under optimal conditions.
Concentration: Lot-specific (to obtain lot-specific concentration and expiration, please enter the lot number in our Certificate of Analysis online tool.)
Storage & Handling: The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application: FC - Quality tested
Recommended Usage: Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is 5 µl per million cells in 100 µl staining volume or 5 µl per 100 µl of whole blood.
Excitation Laser: Red Laser (633 nm)
Application Notes: This clone can suppress anti-CD3 induced T cell proliferation in vitro based on in-house testing.This clone has been tested in-house and determined to not be suitable for applications in immunohistochemistry of paraffin-embedded tissue sections (IHC-P).Additional reported applications (for the relevant formats) include: Blocking1.
Application References(PubMed link indicates BioLegend citation): Stamm H, et al. 2018. Oncogene. Pubmed
Product Citations: Market M, et al. 2022. Int J Mol Sci. 23: . PubMed Gerace D, et al. 2023. Cell Rep Med. 4:100879. PubMed Babl N, et al. 2023. Front Oncol. 13:1107484. PubMed Wang H, et al. 2022. Front Immunol. 13:852436. PubMed Neidleman J, et al. 2020. Elife. 9:00. PubMed Burrack AL, et al. 2019. Cell Rep. 28:2140. PubMed Chen M, et al. 2021. Cancers (Basel). 13:. PubMed Di Blasi D, et al. 2019. Cell Mol Gastroenterol Hepatol. 0.510416667. PubMed Market M, et al. 2020. Front Immunol. 1.127083333. PubMed Kotetsu Y, et al. 2021. Biomedicines. 9:. PubMed Luo Y, et al. 2021. Nat Commun. 12:3913. PubMed Hackstein CP, et al. 2022. Nat Commun. 13:7472. PubMed Tiberti S, et al. 2022. Nat Commun. 13:6752. PubMed
RRID: AB_2632731 (BioLegend Cat. No. 372705) AB_2632732 (BioLegend Cat. No. 372706)
Structure: 26kD; type I transmembrane protein, Ig-like V-type domain, ITIM motif.
Distribution: Activated T cells, Regulatory T cells (Treg), Follicular Helper T cells (TFH), NK cells.
Function: Cell signaling, negative regulation of T cells, T cell tolerance, T cell anergy.
Ligand/Receptor: CD155 (PVR), CD112 (PVRL2, NECTIN-2).
Cell Type: NK cells, T cells, Tfh, Tregs
Biology Area: Cell Adhesion, Cell Biology, Immunology, Inhibitory Molecules, Signal Transduction
Molecular Family: Adhesion Molecules, Immune Checkpoint Receptors
Antigen References: 1. Stanietsky N, et al. 2009. Proc. Natl. Acad. Sci. 106:17858. 2. Yu X, et al. 2009. Nat. Immunol. 10:48. 3. Johnston R, et al. 2014. Cancer Cell. 26:923.
Gene ID: 201633
UniProt: View information about TIGIT on UniProt.org
Clone: A15153G
Regulatory Status: RUO
Other Names: T-cell immunoreceptor with Ig and ITIM domains, VSIG9, VSTM3, WUCAM
Isotype: Mouse IgG2a, κ